Cargando…

Stakeholders’ engagement with Ebola therapy research in resource limited settings

BACKGROUND: The current Ebola Virus Disease (EVD) outbreak in West Africa is the largest in history. As of February 18(th) 2015, 23,258 cases of EVD have been cumulatively reported from Nigeria, Senegal, Guinea, Liberia, Mali, Sierra Leone, Spain, the United Kingdom and the United States of America...

Descripción completa

Detalles Bibliográficos
Autores principales: Folayan, Morenike Oluwatoyin, Brown, Brandon, Haire, Bridget, Yakubu, Aminu, Peterson, Kristin, Tegli, Jemee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480997/
https://www.ncbi.nlm.nih.gov/pubmed/26113124
http://dx.doi.org/10.1186/s12879-015-0950-8
_version_ 1782378226531696640
author Folayan, Morenike Oluwatoyin
Brown, Brandon
Haire, Bridget
Yakubu, Aminu
Peterson, Kristin
Tegli, Jemee
author_facet Folayan, Morenike Oluwatoyin
Brown, Brandon
Haire, Bridget
Yakubu, Aminu
Peterson, Kristin
Tegli, Jemee
author_sort Folayan, Morenike Oluwatoyin
collection PubMed
description BACKGROUND: The current Ebola Virus Disease (EVD) outbreak in West Africa is the largest in history. As of February 18(th) 2015, 23,258 cases of EVD have been cumulatively reported from Nigeria, Senegal, Guinea, Liberia, Mali, Sierra Leone, Spain, the United Kingdom and the United States of America resulting in more than 9,000 deaths. It is therefore exigent to develop prevention and treatment therapies for EVD. DISCUSSION: Several new EVD treatments are in clinical development at this time. Based on lessons learned, four critical processes need to be implemented before clinical trials begin. First, all global EVD research need to be coordinated to promote data sharing and synergistic overlap, while reducing unnecessary duplication of efforts. The World Health Organization is well-placed to undertake such an endeavor. Second, governments of affected nations where trials are being proposed need to lead discussions regarding immediate access to any proven medications for epidemics. Also, governments need to leverage international resources to support and expand existing national expertise to jointly conduct high-caliber clinical research; and resources must be used to enhance local technical skills and expand existing personnel. Third, ethics committees must review protocols, monitor the research process, and work closely with research scientists to insure the ethical integrity of research throughout the trials. Fourth, community advisory boards (CAB) need to be formed, linked with existing community leadership structures and organized in conjunction with trial implementation. These community structures should work together with ethics committees to facilitate the study design, informed consent process, and study implementation. SUMMARY: We must facilitate communication and mutual understanding between trial communities and research teams, and promote positive collaborations between all stakeholders engaged in EVD research. The community engagement process for EVD research is crucial to address myths and misconceptions, and to promote study volunteers’ understanding of the research details. The collaboration between all stakeholders is crucial for continued long term partnership to address EVD outbreak and none of the stakeholders should be left behind in ongoing efforts to develop EVD therapies.
format Online
Article
Text
id pubmed-4480997
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44809972015-06-26 Stakeholders’ engagement with Ebola therapy research in resource limited settings Folayan, Morenike Oluwatoyin Brown, Brandon Haire, Bridget Yakubu, Aminu Peterson, Kristin Tegli, Jemee BMC Infect Dis Debate BACKGROUND: The current Ebola Virus Disease (EVD) outbreak in West Africa is the largest in history. As of February 18(th) 2015, 23,258 cases of EVD have been cumulatively reported from Nigeria, Senegal, Guinea, Liberia, Mali, Sierra Leone, Spain, the United Kingdom and the United States of America resulting in more than 9,000 deaths. It is therefore exigent to develop prevention and treatment therapies for EVD. DISCUSSION: Several new EVD treatments are in clinical development at this time. Based on lessons learned, four critical processes need to be implemented before clinical trials begin. First, all global EVD research need to be coordinated to promote data sharing and synergistic overlap, while reducing unnecessary duplication of efforts. The World Health Organization is well-placed to undertake such an endeavor. Second, governments of affected nations where trials are being proposed need to lead discussions regarding immediate access to any proven medications for epidemics. Also, governments need to leverage international resources to support and expand existing national expertise to jointly conduct high-caliber clinical research; and resources must be used to enhance local technical skills and expand existing personnel. Third, ethics committees must review protocols, monitor the research process, and work closely with research scientists to insure the ethical integrity of research throughout the trials. Fourth, community advisory boards (CAB) need to be formed, linked with existing community leadership structures and organized in conjunction with trial implementation. These community structures should work together with ethics committees to facilitate the study design, informed consent process, and study implementation. SUMMARY: We must facilitate communication and mutual understanding between trial communities and research teams, and promote positive collaborations between all stakeholders engaged in EVD research. The community engagement process for EVD research is crucial to address myths and misconceptions, and to promote study volunteers’ understanding of the research details. The collaboration between all stakeholders is crucial for continued long term partnership to address EVD outbreak and none of the stakeholders should be left behind in ongoing efforts to develop EVD therapies. BioMed Central 2015-06-26 /pmc/articles/PMC4480997/ /pubmed/26113124 http://dx.doi.org/10.1186/s12879-015-0950-8 Text en © Folayan et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Debate
Folayan, Morenike Oluwatoyin
Brown, Brandon
Haire, Bridget
Yakubu, Aminu
Peterson, Kristin
Tegli, Jemee
Stakeholders’ engagement with Ebola therapy research in resource limited settings
title Stakeholders’ engagement with Ebola therapy research in resource limited settings
title_full Stakeholders’ engagement with Ebola therapy research in resource limited settings
title_fullStr Stakeholders’ engagement with Ebola therapy research in resource limited settings
title_full_unstemmed Stakeholders’ engagement with Ebola therapy research in resource limited settings
title_short Stakeholders’ engagement with Ebola therapy research in resource limited settings
title_sort stakeholders’ engagement with ebola therapy research in resource limited settings
topic Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480997/
https://www.ncbi.nlm.nih.gov/pubmed/26113124
http://dx.doi.org/10.1186/s12879-015-0950-8
work_keys_str_mv AT folayanmorenikeoluwatoyin stakeholdersengagementwithebolatherapyresearchinresourcelimitedsettings
AT brownbrandon stakeholdersengagementwithebolatherapyresearchinresourcelimitedsettings
AT hairebridget stakeholdersengagementwithebolatherapyresearchinresourcelimitedsettings
AT yakubuaminu stakeholdersengagementwithebolatherapyresearchinresourcelimitedsettings
AT petersonkristin stakeholdersengagementwithebolatherapyresearchinresourcelimitedsettings
AT teglijemee stakeholdersengagementwithebolatherapyresearchinresourcelimitedsettings